Remnant cholesterol in the era of intensive lipid-lowering therapies
- PMID: 37322804
- DOI: 10.1093/eurheartj/ehad298
Remnant cholesterol in the era of intensive lipid-lowering therapies
Conflict of interest statement
Conflict of interest B.G.N. reports consultancies and talks sponsored by AstraZeneca, Sanofi, Regeneron, Akcea, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Abbott, and Silence Therapeutics. There are no competing interests for B.N.W., A.B.W., or K.M.P.
Comment in
-
Remnant cholesterol as a lipid-lowering target may have a long way to go.Eur Heart J. 2023 Sep 21;44(36):3481-3482. doi: 10.1093/eurheartj/ehad256. Eur Heart J. 2023. PMID: 37322602 No abstract available.
Comment on
-
Remnant cholesterol as a lipid-lowering target may have a long way to go.Eur Heart J. 2023 Sep 21;44(36):3481-3482. doi: 10.1093/eurheartj/ehad256. Eur Heart J. 2023. PMID: 37322602 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical